DE69231473D1 - Immunochemischer nachweiss von endprodukten der fortgeschrittenen glycosylation in vivo - Google Patents

Immunochemischer nachweiss von endprodukten der fortgeschrittenen glycosylation in vivo

Info

Publication number
DE69231473D1
DE69231473D1 DE69231473T DE69231473T DE69231473D1 DE 69231473 D1 DE69231473 D1 DE 69231473D1 DE 69231473 T DE69231473 T DE 69231473T DE 69231473 T DE69231473 T DE 69231473T DE 69231473 D1 DE69231473 D1 DE 69231473D1
Authority
DE
Germany
Prior art keywords
advanced glycosylation
disclosed
age
vivo
glycosylation endproducts
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69231473T
Other languages
English (en)
Other versions
DE69231473T2 (de
Inventor
J Bucala
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rockefeller University
Original Assignee
Rockefeller University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rockefeller University filed Critical Rockefeller University
Application granted granted Critical
Publication of DE69231473D1 publication Critical patent/DE69231473D1/de
Publication of DE69231473T2 publication Critical patent/DE69231473T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6842—Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/72—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood pigments, e.g. haemoglobin, bilirubin or other porphyrins; involving occult blood
    • G01N33/721—Haemoglobin
    • G01N33/723—Glycosylated haemoglobin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE69231473T 1991-12-20 1992-12-21 Immunochemischer nachweiss von endprodukten der fortgeschrittenen glycosylation in vivo Expired - Fee Related DE69231473T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US81157991A 1991-12-20 1991-12-20
US07/956,849 US5624804A (en) 1991-12-20 1992-10-01 Immunochemical detection of In vivo advanced glycosylation end products
PCT/US1992/011158 WO1993013421A1 (en) 1991-12-20 1992-12-21 Immunochemical detection of in vivo advanced glycosylation endproducts

Publications (2)

Publication Number Publication Date
DE69231473D1 true DE69231473D1 (de) 2000-10-26
DE69231473T2 DE69231473T2 (de) 2001-02-08

Family

ID=27123501

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69231473T Expired - Fee Related DE69231473T2 (de) 1991-12-20 1992-12-21 Immunochemischer nachweiss von endprodukten der fortgeschrittenen glycosylation in vivo

Country Status (12)

Country Link
US (6) US5624804A (de)
EP (1) EP0623216B1 (de)
JP (1) JPH07502534A (de)
KR (1) KR100257733B1 (de)
CN (1) CN1053964C (de)
AT (1) ATE196549T1 (de)
AU (1) AU681340B2 (de)
CA (1) CA2126209A1 (de)
DE (1) DE69231473T2 (de)
ES (1) ES2150936T3 (de)
PT (1) PT101147A (de)
WO (1) WO1993013421A1 (de)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5869534A (en) * 1992-05-21 1999-02-09 The Picower Institute For Medical Research Glycosylation of lipids and lipid-containing particles, and diagnostic and therapeutic methods and materials derived therefrom
US7585512B1 (en) * 1990-05-08 2009-09-08 Thomas Jefferson University Composition and method of using tumor cells
US5624804A (en) * 1991-12-20 1997-04-29 The Rockefeller University Immunochemical detection of In vivo advanced glycosylation end products
AU712004B2 (en) * 1993-03-11 1999-10-28 Picower Institute For Medical Research, The Glycosylation of lipids and lipid-containing particles, and diagnostic and therapeutic methods and materials derived therefrom
JPH09511492A (ja) * 1994-02-03 1997-11-18 ザ ピコワー インスティテュート フォア メディカル リサーチ アミロイドーシスの前進性グリコシル化終末産物仲介モジュレーション用組成物及び方法
US6410598B1 (en) 1994-02-03 2002-06-25 Michael P. Vitek Compositions and methods for advanced glycosylation endproduct-mediated modulation of amyloidosis
US5610076A (en) * 1994-04-29 1997-03-11 Alteon Inc. Method for detecting hemoglobin advanced glycosylation endproducts
EP0801658B1 (de) * 1994-12-30 2003-07-16 Alteon, Inc. Monoklonale antikörper spezifisch für endprodukte der fortgeschrittenen glycosylation in biologischen proben
US5744318A (en) * 1994-12-30 1998-04-28 Alteon Inc. Monoclonal antibody for the detection of advanced glycosylation endproducts in biological samples
MX9705449A (es) * 1995-01-18 1998-02-28 Alteon Inc Uso de compuestos de tiazolio para evitar y revertir la formacion de productos finales de glicosilacion avanzada.
US5811242A (en) * 1995-10-24 1998-09-22 Tokuyama Corporation Marker and reagent for diabetes mellitus and diabetes mellitus complication
US5811401A (en) * 1995-11-30 1998-09-22 The Picower Institute For Medical Research Advanced glycosylation endproducts and methods of use therefor
EP0877943A1 (de) * 1995-12-26 1998-11-18 The Picower Institute For Medical Research Methoden zur messung und behandlung auf grund von endprodukten der fortgeschrittenen glycosylation im tabak und seinen verbrennungsnebenprodukten
WO1997024372A1 (en) * 1995-12-29 1997-07-10 Alteon Inc. 6-(n-carboxymethylamino)caproate, salts thereof and methods of use therefor
US6033862A (en) * 1996-10-30 2000-03-07 Tokuyama Corporation Marker and immunological reagent for dialysis-related amyloidosis, diabetes mellitus and diabetes mellitus complications
US6380165B1 (en) 1997-09-19 2002-04-30 The Picower Institute For Medical Research Immunological advanced glycation endproduct crosslink
US6728560B2 (en) 1998-04-06 2004-04-27 The General Hospital Corporation Non-invasive tissue glucose level monitoring
US6505059B1 (en) 1998-04-06 2003-01-07 The General Hospital Corporation Non-invasive tissue glucose level monitoring
US20020091324A1 (en) * 1998-04-06 2002-07-11 Nikiforos Kollias Non-invasive tissue glucose level monitoring
US7899518B2 (en) * 1998-04-06 2011-03-01 Masimo Laboratories, Inc. Non-invasive tissue glucose level monitoring
US6721582B2 (en) 1999-04-06 2004-04-13 Argose, Inc. Non-invasive tissue glucose level monitoring
CN2445326Y (zh) * 2000-10-09 2001-08-29 刘永详 测定被糖化蛋白的免疫分析装置
ATE283481T1 (de) * 2001-03-22 2004-12-15 Hoffmann La Roche Verfahren zum auffinden von reagenzien und festphasenkomponenten in spezifischen bindungsassays, frei von fortgeschrittenen glykosylierungsendprodukten
MY140679A (en) * 2001-05-24 2010-01-15 Avanir Pharmaceuticals Inhibitors of macrohage migration inhibitory factor and methods for identifying the same
GB0221686D0 (en) * 2002-09-19 2002-10-30 Univ Ulster Biomarker
TW200418829A (en) * 2003-02-14 2004-10-01 Avanir Pharmaceutics Inhibitors of macrophage migration inhibitory factor and methods for identifying the same
AU2004268941A1 (en) * 2003-08-22 2005-03-10 Avanir Pharmaceuticals Substituted naphthyridine derivatives as inhibitors of macrophage migration inhibitory factor and their use in the treatment of human diseases
CN100489526C (zh) * 2004-01-16 2009-05-20 中国人民解放军军事医学科学院放射与辐射医学研究所 一种人脑红蛋白检测及诊断试剂盒，其制备方法及用途
AU2006227297A1 (en) * 2005-03-24 2006-09-28 Avanir Pharmaceuticals Thienopyridinone derivatives as macrophage migration inhibitory factor inhibitors
GB0605689D0 (en) * 2006-03-21 2006-05-03 Novartis Ag Organic compounds
ES2522816T3 (es) * 2006-03-24 2014-11-18 Metanomics Gmbh Procedimiento para predecir la diabetes de tipo II
DE102006026173A1 (de) * 2006-06-06 2007-12-20 Fachhochschule Südwestfalen Verfahren zur nichtinvasiven Diagnose von Diabetes
US20110105961A1 (en) 2008-05-23 2011-05-05 Gruber Lewis S Methods, compositions and apparatuses for facilitating regeneration
US9060687B2 (en) 2009-10-02 2015-06-23 Sharp Kabushiki Kaisha Device for monitoring blood vessel conditions and method for monitoring same
JP5386634B2 (ja) * 2010-03-19 2014-01-15 シャープ株式会社 測定結果処理装置、測定システム、測定結果処理方法、制御プログラムおよび記録媒体
ES2725852T3 (es) * 2010-09-27 2019-09-27 Siwa Corp Eliminación selectiva de células modificadas por AGE para el tratamiento de la aterosclerosis
US8721571B2 (en) 2010-11-22 2014-05-13 Siwa Corporation Selective removal of cells having accumulated agents
KR101939401B1 (ko) 2011-11-10 2019-01-16 가천대학교 산학협력단 단핵식세포계 세포의 ａｇｅ-알부민 합성 또는 분비 저해제를 유효성분으로 포함하는 허혈성 심장질환 예방 또는 치료용 조성물
ES2908203T3 (es) * 2014-09-19 2022-04-28 Siwa Corp Anticuerpos anti-age para el tratamiento de inflamación y trastornos autoinmunes
US10358502B2 (en) 2014-12-18 2019-07-23 Siwa Corporation Product and method for treating sarcopenia
US9993535B2 (en) 2014-12-18 2018-06-12 Siwa Corporation Method and composition for treating sarcopenia
JP2018535953A (ja) * 2015-10-13 2018-12-06 シワ コーポレーション 抗ａｇｅ抗体およびその使用方法
JP6553491B2 (ja) * 2015-11-26 2019-07-31 オリエンタル酵母工業株式会社 最終糖化産物（ＡＧＥｓ）が関連する疾患の罹患又はそのリスクを予測する方法
RU2728964C2 (ru) 2016-02-19 2020-08-03 Сива Корпорейшн Способ и композиция для лечения рака, уничтожения метастатических раковых клеток и профилактики метастазов рака, используя антитела к конечным продуктам повышенного гликирования ( AGE)
CN109311975A (zh) 2016-04-15 2019-02-05 Siwa有限公司 用于治疗神经退行性紊乱的抗age抗体
US11213585B2 (en) 2016-06-23 2022-01-04 Siwa Corporation Vaccines for use in treating various diseases and disorders
CN106769349B (zh) * 2017-01-06 2020-01-21 上海君联医疗设备有限公司 血液中异常糖基化蛋白细胞的检测方法
US10925937B1 (en) 2017-01-06 2021-02-23 Siwa Corporation Vaccines for use in treating juvenile disorders associated with inflammation
US10858449B1 (en) 2017-01-06 2020-12-08 Siwa Corporation Methods and compositions for treating osteoarthritis
US10961321B1 (en) 2017-01-06 2021-03-30 Siwa Corporation Methods and compositions for treating pain associated with inflammation
US10995151B1 (en) 2017-01-06 2021-05-04 Siwa Corporation Methods and compositions for treating disease-related cachexia
CA3059803A1 (en) 2017-04-13 2018-10-18 Siwa Corporation Humanized monoclonal advanced glycation end-product antibody
CN110832327A (zh) * 2017-05-04 2020-02-21 Siwa有限公司 诊断性晚期糖基化终末产物抗体
US11518801B1 (en) 2017-12-22 2022-12-06 Siwa Corporation Methods and compositions for treating diabetes and diabetic complications
CN108776131B (zh) * 2018-03-19 2020-06-09 深圳市南山区疾病预防控制中心 一种食品中AGEs含量的检测方法
WO2020023532A1 (en) 2018-07-23 2020-01-30 Siwa Corporation Methods and compositions for treating chronic effects of radiation and chemical exposure
EP3840840A1 (de) 2018-08-23 2021-06-30 Siwa Corporation Anti-carboxymethyl-lysin-antikörper und ultraschall zur entfernung von altersmodifizierten zellen
CN111040001B (zh) * 2019-12-27 2021-04-16 山西医科大学 安定代谢物葡萄糖醛酸结合物的制备方法
CN115996954A (zh) 2020-05-01 2023-04-21 Siwa有限公司 治疗感染的方法
WO2022093195A1 (en) 2020-10-27 2022-05-05 Siwa Corporation Methods and compositions for treating osteoarthritis using anti-age antibodies or age antigens
WO2022125776A2 (en) 2020-12-09 2022-06-16 Siwa Corporation Methods and compositions for treating kidney diseases
WO2023023654A1 (en) 2021-08-20 2023-02-23 Siwa Corporation Methods and compositions for treating fibrotic diseases
WO2024102157A1 (en) 2022-11-09 2024-05-16 Siwa Corporation Methods and compositions for treating diabetes and diabetic complications

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3654090A (en) * 1968-09-24 1972-04-04 Organon Method for the determination of antigens and antibodies
NL154598B (nl) * 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US4016043A (en) * 1975-09-04 1977-04-05 Akzona Incorporated Enzymatic immunological method for the determination of antigens and antibodies
US4867973A (en) * 1984-08-31 1989-09-19 Cytogen Corporation Antibody-therapeutic agent conjugates
JPH0766253B2 (ja) * 1986-06-20 1995-07-19 松下電器産業株式会社 マトリクス型画像表示装置
JP2644767B2 (ja) * 1986-09-12 1997-08-25 ザ ロックフェラー ユニバーシティ 後生的なグリコシル化最終産物を除去する為の方法及び薬剤
DE3882855T2 (de) * 1987-09-17 1994-03-24 Rockefeller University New Yor Glycosylierte Endstoffe und damit verbundene Verfahren.
US5223392A (en) * 1988-01-25 1993-06-29 Exocell, Inc. Monoclonal antibodies against glycated albumin, hybrid cell lines producing these antibodies, and use therefore
US5624804A (en) * 1991-12-20 1997-04-29 The Rockefeller University Immunochemical detection of In vivo advanced glycosylation end products

Also Published As

Publication number Publication date
JPH07502534A (ja) 1995-03-16
US5733546A (en) 1998-03-31
CA2126209A1 (en) 1993-07-08
CN1053964C (zh) 2000-06-28
US5629408A (en) 1997-05-13
ATE196549T1 (de) 2000-10-15
EP0623216A1 (de) 1994-11-09
US5624804A (en) 1997-04-29
US5702704A (en) 1997-12-30
AU681340B2 (en) 1997-08-28
DE69231473T2 (de) 2001-02-08
CN1079825A (zh) 1993-12-22
ES2150936T3 (es) 2000-12-16
PT101147A (pt) 1994-03-31
EP0623216B1 (de) 2000-09-20
KR940704003A (ko) 1994-12-12
US5683887A (en) 1997-11-04
KR100257733B1 (ko) 2000-06-01
WO1993013421A1 (en) 1993-07-08
AU3418793A (en) 1993-07-28
US5712101A (en) 1998-01-27

Similar Documents

Publication Publication Date Title
DE69231473D1 (de) Immunochemischer nachweiss von endprodukten der fortgeschrittenen glycosylation in vivo
SE8103759L (sv) Blodkoagulationsbefremjande preparation basera pa humanproteiner liksom sett att framstella densamma
ATE249476T1 (de) Cyclin d1 und seine cdna
DE3685625D1 (de) Antikoerperkomplexe von haptenmodifizierten diagnostischen oder therapeutischen mitteln.
ATE239797T1 (de) Antikörper gegen beta-amyloid oder derivative davon und seine verwendung
BE852195A (fr) Matieres alimentaires pour l'homme et pour les animaux
EE9400356A (et) Polüetüleenglükool proteiin konjugaadid, ühendid, nende kasutamine, meetod konjugaatide valmistamiseks ja ravimvormid
DK0403156T3 (da) Forbedrede monoklonale antistoffer mod den humane alfa/beta-T-cellereceptor samt fremstilling og anvendelse deraf
DE69937899D1 (de) Antikörper-serumprotein hybride
EE9600192A (et) Antikehad, mis seostuvad putuka soole valkudele, ja nende kasutamine
Watanabe et al. The binding of human milk lactoferrin to immunoglobulin A
DE68925226D1 (de) Monoklonale Antikörper
DK0386906T3 (da) Lymfocyt-associeret celleoverfladeprotein
IT8483359A0 (it) Procedimento per ottenere lapreparazione di concentrati e nutrimenti proteici dal sangue animale.
IT1136217B (it) Macchina per la fienagione in particolare per il rivoltamento e l anda natura di fieno o foraggio
SE8502997L (sv) Forfarande for framstellning av medicinska kosmetiska kompositioner
FI885169A (fi) Monoklonaalinen vasta-aine, joka tunnistaa N-asetyylineuramiinihapon -järjestyksessä, sen käyttö ja sitä tuottava hybridooma
IT8021086A0 (it) Preparazione. vello animale sgrassato eprocedimento per la sua
JPS58501543A (ja) ヒトインタ−フエロン蛋白とヒトインタ−フエロン蛋白に対する抗体に関する改良
ATE407944T1 (de) Mit trp-proteinen verwandtes protein mtr1 und dieses codierende dna-sequenz
DE69232975D1 (de) Protein p100von menschlichem Herpesvirus Typ 6, die korrespondierenden DNS Squenzen, ihre Herstellung und Verwendung
FI971879A0 (fi) Allogeenisten ja ksenogeenisten proteiinien vasta-aineet, niiden käyttö diagnoosissa ja hoidossa ja menetelmät niiden määrittämiseksi
SE8002602L (sv) Diagnostiskt forfarande
ES2067058T3 (es) Tratamiento de carnes.
ATE125306T1 (de) Monoklonale antikörper, die einen unterschied zwischen nativproteinen und proteinen mit einer modifizierten sequenz machen.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee